Pennsylvania Real Estate Investment Trust 6.875% Cum Red Perp Pfd Shs Series -D- Stock (OTC: PRTNQ)

Latest news for Pennsylvania Real Estate Investment Trust 6.875% Cum Red Perp Pfd Shs Series -D- (OTC:PRTNQ) Stock

Pennsylvania Real Estate Investment Trust 6.875% Cum Red Perp Pfd Shs Series -D-

SentryBay, the leaders in endpoint protection, has come to a partnership agreement with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tdsynnex.com%2F&amp;esheet=54128153&amp;newsitemid=20241001401104&amp;lan=en-US&amp;anchor=TD+SYNNEX&amp;index=1&amp;md5=9a5fe7780f38099e1cf990365da25505">TD SYNNEX</a>, a leading global distributor and solutions aggregator for the IT ecosystem. As a result, TD SYNNEX will add SentryBay's Armored Client solution for Microsoft AVD and W365 environments to its extensive portfolio.
The partnership will initially serve TD SYNNEX's channel network of resellers in the USA and Canada, with plans to expand globally in the future, particularly into Europe and Asia.
SentryBay's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsentrybay.com%2Farmored-client%2F&amp;esheet=54128153&amp;newsitemid=20241001401104&amp;lan=en-US&amp;anchor=Armored+Client&amp;index=2&amp;md5=899cee39086dc909697514e5d8dab765">Armored Client</a> provides an impenetrable defensive layer that once deployed on an end point isolates and protects a DaaS session and all applications run within it from keyloggers, screen capture and malicious process injection to remove the risk from data leakage and credential theft without any need to identify the threat first. This simplified, yet effective solution is targeted at enterprises, as well as SMEs using Microsoft AVD and W365.
By partnering with TD SYNNEX, SentryBay offers a differentiated solution to the distributor's partner ecosystem, which meets the needs of organizations adopting BYOD business models operating within AVD and W365, ensuring their security product portfolio remains at the forefront of innovation. While SentryBay will provide a unique element in the specialty security portfolio at TD SYNNEX, it will also complement existing vendors and solutions, including those from Microsoft.

News

MSFT

SentryBay Partners with TD SYNNEX to Boost Endpoint Security for Microsoft AVD and W365 Users

The recently closed amendment provides an increase in total commitments from&nbsp;$430.0 million&nbsp;to&nbsp;$600.0 million, while maintaining an expanded accordion feature that allows for an increase up to&nbsp;$800.0 million&nbsp;of total commitments from new and existing lenders on the same terms and conditions as the existing commitments.

MAIN

Main Street Says Subsidiary MSCC Funding Recently Amended Its Special Purpose Vehicle Revolving Credit Facility

QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) ("QuantaSing" or the "Company"), a leading lifestyle solution provider empowering adults to live better and longer, today announced that its board of directors (the "Board") has approved the declaration and distribution of a special dividend (the "Special Dividend") of US$0.067 per ordinary share (US$0.201 per American depositary share, or ADS). &nbsp;
The aggregate amount of the Special Dividend will be approximately US$11 million, which is payable in U.S. dollars and in cash, and will be funded by surplus cash and to be paid out from the share premium account of the Company. The dividends are expected to be paid on or around November 7, 2024 to the holders of the Company's ordinary shares, and on or around November 15, 2024 to the holders of the ADSs, of record, as of the close of business on October 30, 2024. Dividend to be paid to the holders of ADSs issued by the depositary of the ADSs will be subject to the terms of the deposit agreement.

Dividends

QuantaSing Group Declared A Special Dividend Of $0.201/ADS

BLCO

Bausch + Lomb Announces U.S. Launch Of Opal Digital E-commerce Marketplace

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) with a Buy and maintains $36 price target.

Price Target

Reiteration

Analyst Ratings

VRNA

HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $36 Price Target

B of A Securities analyst Tazeen Ahmad maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Neutral and lowers the price target from $33 to $31.

PRTA

B of A Securities Maintains Neutral on Prothena Corp, Lowers Price Target to $31

D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) ("D-Wave" or the "Company"), a leader in quantum computing systems, software, and services and the world's first commercial supplier of quantum computers, and the pharmaceutical division of Japan Tobacco Inc. ("JT") today announced plans to collaborate on a joint proof-of-concept project that will leverage quantum computing technology and artificial intelligence ("AI") in the drug discovery process, i.e., "Quantum AI-driven Drug Discovery."
Supported by D-Wave's team of professional services experts, the AI team in JT's pharmaceutical division will utilize D-Wave's annealing quantum computing solutions as accelerators in the speed and quality of training JT's novel AI-driven analysis systems, aiming to extend the applicable range of such AI systems in the drug discovery field (AI-driven Drug Design). The goal of the project is to pioneer a new process for discovering 'first-in-class' pharmaceutical small compounds.
"In our development of AI-driven drug discovery systems, we have been focusing on and researching quantum computing technologies as a speed and quality accelerator in the drug design process," said Dr. Masaru Tateno, Chief Scientific Officer (CSO) of JT's Pharmaceutical Research Center. "In this context, we examine our novel theory and systems in our joint proof-of-concept project, and thus we have high expectations for the effectiveness of D-Wave's annealing quantum computing solutions. By utilizing D-Wave's quantum technology, we aim to pioneer a new standard that significantly accelerates the speed and quality of drug discovery and expands the exploration space for pharmaceutical small compounds."
"Pharmaceutical companies need to maintain competitiveness while addressing the challenges of difficulty, uncertainty, and duration in new drug development, creating an environment that is accelerating the speed and quality for AI drug discovery," said Dr. Alan Baratz, CEO of D-Wave. "D-Wave is committed to supporting JT's pharmaceutical division in maximizing the capabilities of AI through quantum computing technology, with the goal of expanding the exploration space for pharmaceutical small compounds."
Following the proof-of-concept project, JT's pharmaceutical division plans to further advance the developed, Quantum AI-driven Drug Discovery analysis systems and eventually move the application of quantum computing technology into production operations.

QBTS

D-Wave and Japan Tobacco Collaborate on Quantum AI-Driven Drug Discovery Project

GRMN

Garmin Unveils New Fusion Apollo Marine Speakers And Subwoofers That Merge Premium Sound Quality With Enhanced Visual Features

Adeia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>), the company whose patented innovations enhance billions of devices and shape the way the world explores and experiences entertainment, today announced it has renewed its intellectual property (IP) license agreement with leading TV seller VIZIO. Under the terms of the agreement, the multi-year license renewal extends VIZIO's access to Adeia's media IP portfolio for its products and services. &nbsp;
"We are excited to enter into this renewal with VIZIO, a leader in the digital entertainment space," said Mark Kokes, Adeia's chief licensing officer and general manager, media. "This agreement demonstrates the continued value and relevance of our technology."

ADEA

VZIO

Adeia Extends Media IP License Deal with VIZIO, Strengthening Digital Entertainment

Baird analyst Jonathan Komp maintains Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) with a Neutral and raises the price target from $140 to $167.

BOOT

Baird Maintains Neutral on Boot Barn Holdings, Raises Price Target to $167

Marex Group Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>), the diversified global financial services platform, today announces the completion of its acquisition of Dropet, a Spanish biofuels company, expanding its range of renewables products as it continues to grow its global environmental products business. The acquisition is aligned with Marex's strategy to diversify its business and increase earnings resilience. &nbsp;
Dropet offers execution services for both physical and paper biofuels products across Europe, Latin America, the Middle East and Africa. It has more than 18 years' experience in physical ethanol and related biofuel products, as well as exchange-traded ethanol products. It also operates a successful annual biofuels conference.
Acquiring Dropet gives Marex additional capabilities in physical biofuels products and a high-quality, experienced team. It is aligned with Marex's strategy to increase the scale, diversification and global footprint of its environmental products offering as it seeks to be a leading provider of environmental commodities and support clients with the transition to a low carbon economy. Marex has a strong track-record of acquiring businesses and enabling them to grow.

Marex Group Snapped Dropet, A Spanish Biofuels Company, Financial Terms Undisclosed

In the initial phase of the partnership, Zapata will build foundational elements of MAG&#39;s next-generation integrated surveillance platform.

ZPTA

Zapata AI Inks First Commercial Agreement Of Its Partnership With MAG Aerospace

Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading enzyme engineering company, today announced it has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme LLC, part of Maravai LifeSciences, for multiple enzymes in Codexis' life science enzyme portfolio. The agreement includes licenses for the HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes that were in development directed towards genomics and diagnostics applications prior to the Company's strategic shift announced in July 2023. Under the terms of the agreement, Codexis is eligible to receive sales-based royalties. &nbsp;
"As our manufacturing partner for the past three years—and with an existing genomics enzyme portfolio and sales force —Alphazyme is the natural choice to extend our commercial reach into this segment. We anticipate a smooth transition for our customers as there is no change in manufacturing supply and many of our customers are already familiar with the Alphazyme team," said Kevin Norrett, MBA, Chief Operating Officer at Codexis. "This transaction enables Codexis to maintain its focus on maximizing our near-term commercial opportunities and strategic priorities. This includes the growth of our Pharmaceutical Manufacturing business, increasing commercial adoption of the dsRNA ligase, and the build-out of our ECO Synthesis&#x2122; Innovation Lab to support manufacturing process development for our customers' preclinical siRNA assets. We remain on track to achieve key milestones for the ECO Synthesis&#x2122; platform this fiscal year, while delivering double-digit product revenue growth and maintaining a path to positive cash flow around the end of 2026."
Alphazyme is a premier partner for industrial-scale molecular biology enzymes. Alphazyme enthusiastically collaborates with manufacturers of nucleic acid synthesis and detection platforms to produce affordable, custom enzyme formulations of the highest quality that meet the specifications of the rapidly expanding markets for custom DNA and RNA molecules, genomic medicines and genetic testing.&nbsp;"The Codexis and Alphazyme relationship has been strong for many years. We are excited to take on Codexis' portfolio of high-performing life science and diagnostic enzymes and be a part of their continued success," said Chad Decker, Vice President and General Manager of Alphazyme. This new collaboration will leverage the experience and industry knowledge of the Alphazyme team to enhance the commercialization of Codexis' portfolio of life science and diagnostic enzymes.
This license agreement marks another transaction in which Codexis is executing on its strategy to divest the Company's non-core assets following its strategic shift to focus on the growth of its Pharmaceutical Manufacturing business and Enzyme Catalyzed Oligonucleotide (ECO) Synthesis&#x2122; manufacturing platform.

CDXS

MRVI

Codexis Licenses Key Enzymes to Alphazyme, Sharpening Focus on Pharmaceutical Growth

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) with a Buy and maintains $30 price target.

ANVS

HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target

Surmodics expects to initiate limited market release for the Pounce XL Thrombectomy System in the first half of 2025, with commercialization planned following the completion of the limited market release.

SRDX

Surmodics Receives FDA 510(k) Clearance For Pounce XL Thrombectomy System

Eyenovia, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>), an ophthalmic technology company, today announced that the Company has commenced manufacturing of registration batches of its FDA-approved mydriasis product, Mydcombi, a key step in the approval process for its state-of-the-art Gen-2 Optejet dispensing platform. &nbsp;
Mydcombi will undergo 12-month stability testing and other functional testing in the Gen-2 Optejet device that is consistent with feedback from the Type-C meeting on Eyenovia's device qualification plan that the Company received from the FDA in July.
"We were very pleased to have received feedback from the FDA that was very consistent with our Gen-2 qualification plan, allowing us to move forward with manufacturing and testing as quickly and efficiently as possible," stated Michael Rowe, Chief Executive Officer of Eyenovia. "With advances from the prior generation product, including one-button use and compatibility with our digital compliance monitoring program, Optecare&#x2122;, we view the introduction of the Gen-2 Optejet as a significant upcoming inflection point for our company."
"Importantly, the work that we are doing for Mydcombi in the Gen-2 Optejet device may also provide significantly lower manufacturing costs and streamline future regulatory interactions as we expand the Gen-2 platform to additional therapeutics, both within our own pipeline as well as those in development partnerships, such as dry eye," Mr. Rowe concluded.
Eyenovia anticipates completion of testing of its Mydcombi registration batches by the end of next year, with a potential SNDA filing in early 2026.&nbsp;&nbsp;

Government

Regulations

EYEN

Eyenovia Begins Manufacturing Mydcombi for Gen-2 Optejet Platform, Eyes FDA Progress

Earnings

Guidance

General

UNFI

United Natural Foods Expects Fiscal Year 2025 Adjusted EPS Of $0.20-$0.80 Versus Consensus Of $0.57

The agreement was due to expire in April 2026.

Management

CIGI

Colliers Extends Term Of Existing Management Services Agreement With Its Global Chairman And CEO And Largest Shareholder, Jay S. Hennick, To January 1, 2029

PolyPid Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled the last patient required in order to conduct the planned unblinded interim analysis in its ongoing SHIELD II Phase 3 trial for D-PLEX100&nbsp;for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions.&nbsp;The unblinded interim analysis will be conducted during the current quarter, following the completion of the 30-day follow-up assessment for the last patient. The unblinded interim analysis may allow for early trial conclusion due to positive efficacy, continuation to planned patient recruitment (up to 630 subjects), sample size re-assessment, or futility.
Approximately 430 subjects have been enrolled to date in the SHIELD II Phase 3 trial.
"We are pleased to reach this important milestone in our ongoing SHIELD II Phase 3 trial and look forward to the unblinded interim analysis later this quarter," said Dikla Czaczkes Akselbrad, PolyPid's Chief Executive Officer. "Enrollment in the study is accelerating and we remain on track to announce top-line results from&nbsp;SHIELD II&nbsp;in the first quarter of 2025. Importantly, SHIELD II is now nearly three-quarters enrolled to full planned enrollment, which is expected by year-end."
Under the terms of the private placement financing that was closed in January 2024 ("January PIPE"), PolyPid has the potential to secure an additional&nbsp;$18.5 million&nbsp;if the unblinded interim analysis of its SHIELD II Phase 3 trial of D-PLEX100 results in the stopping of the trial due to positive efficacy and all warrants are exercised. In addition, under the terms of the private placement financing that was closed in August 2024 ("August PIPE"), PolyPid has the potential to secure an additional&nbsp;$6.1 million&nbsp;if the unblinded interim analysis results in either the stopping of the trial due to positive efficacy, or continuation to planned patient recruitment (up to 630 subjects) and all warrants are exercised. If all the warrants issued in the August PIPE are exercised, the Company&nbsp;would be funded beyond top-line results. If all warrants issued in both January PIPE and August PIPE are exercised, the Company&nbsp;would be funded into 2026.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Pennsylvania Real Estate Investment Trust 6.875% Cum Red Perp Pfd Shs Series -D-

News

Latest news for Pennsylvania Real Estate Investment Trust 6.875% Cum Red Perp Pfd Shs Series -D- (OTC:PRTNQ) Stock